Lallemand offers pharma industry bacteria production
Customers given access to patented technology for the protection of live bacteria
Lallemand Inc, a Canadian manufacturer of yeast and bacteria, has launched Lallemand Manufacturing Services, to offer its expertise in bacteria development and industrial production to the pharmaceutical industry worldwide.
Lallemand Manufacturing Services will support its customers from development to finished product manufacturing to the highest quality standards (ICHQ7A up to GMP for finished product compliance).
In addition, the firm will offer access to its patented technology for the protection of live bacteria for specific applications, including STAR enterocoating technology and Probiocap microencapsulation technology.
Lallemand will offer process development, scale-up, industrial production (fermentation, freeze-drying, formulation, packaging). It will provide anything from bulk active ingredients to ready-to-market finished products.
Lallemand Manufacturing Services operates three bacteria production facilities in France (Aurillac), Canada (Montreal) and in US (Milwaukee), offering flexible production capacities, from pilot bioreactors (2L up to 100L) for process development up to 20m3 bioreactor for large-scale fermentations.
